Dopamine (DA) dysfunction is implicated in a variety of neuropsychiatric disorders. Actions of DA are mediated through the DA DI through D5 receptors. Considerable interest has centered upon D2 receptors (D2Rs) because most antipsychotic drugs in clinical use have affinity for the D2R. Recent studies have shown that these drugs exert some their actions not only through G protein-dependent inhibition of cAMP production, but also though G protein-independent mechanisms that involve B-arrestin2 (PArr2) signaling complexes. Interestingly, the BArr2 pathway appears to be particularly important for the actions of antipsychotic drugs in vivo. Daily injection of high doses of clozapine or aripiprazole for 14 days was sufficient to reduce phencyclidine (PCP) stimulated hyperlocomotion in wild type (WT) mice;this decrease in activity was ineffective in BArr2 knockout (KO) mice. Using compounds based on the structure of aripirazole, we have identified several BArr-selective agents and find that they possess antipsychotic activity in vivo in the open field in C57BL/6 mice given amphetamine (AMPH) or PCP. Antispychotic activity was observed also in WT mice, but was lost or attenuated in BArr2-K0 animals. Importantly, these same compounds induced catalepsy in the BArr2-K0 mice, but not in WT controls. Thus, BArr2 pathway seems important for antipsychotic actions, whereas the Gi/o pathway appears to mediate the side-effect of these drugs. The Overall Goal of the proposed research in the Behavioral Core is provide preclinical behavioral data that can be supportive for taking a novel compound(s) with functional selectivity into clinical trials. These compounds will be evaluated in behavioral tests designed to model the positive, negative, and cognitive symptoms of schizophrenia-like responses in mice. Effects of acute injection will be assessed in the AMPH and PCP models with C57BL/6 and pArr2 mice to demonstrate specificity of action. Effects of chronic injection will be analyzed in genetic models of hyperdopaminergia (DA transporter KO) and hypoglutaminergia (NR1 subunit knockdown) as well as in the pArr2 mice. Additional behavioral studies will be conducted with the mice described in Project #2 (Dr. Marc Caron) where together we will identify the molecular and cellular mechanisms of the lead compounds as they relate to behavior.

Public Health Relevance

Our aripiprazole-related compounds take advantage of functional selectivity of the D2R by selectively targeting the Gi/o or BArr pathways. With this approach we may ameliorate the positive-, negative-, and/or cognitive-like symptoms of schizophernia-like behaviors in our mouse models and understand the mechanisms of this response. Collectively, our behavioral studies should help identify a novel compound(s) that can be taken into clinical trials.

National Institute of Health (NIH)
National Institute of Mental Health (NIMH)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZMH1-ERB-C)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
Rose, Samuel J; Pack, Thomas F; Peterson, Sean M et al. (2017) Engineered D2R Variants Reveal the Balanced and Biased Contributions of G-Protein and ?-Arrestin to Dopamine-Dependent Functions. Neuropsychopharmacology :
Urs, Nikhil M; Peterson, Sean M; Caron, Marc G (2017) New Concepts in Dopamine D2 Receptor Biased Signaling and Implications for Schizophrenia Therapy. Biol Psychiatry 81:78-85
Wacker, Daniel; Wang, Sheng; McCorvy, John D et al. (2017) Crystal Structure of an LSD-Bound Human Serotonin Receptor. Cell 168:377-389.e12
Wacker, Daniel; Stevens, Raymond C; Roth, Bryan L (2017) How Ligands Illuminate GPCR Molecular Pharmacology. Cell 170:414-427
Wang, Sheng; Wacker, Daniel; Levit, Anat et al. (2017) D4 dopamine receptor high-resolution structures enable the discovery of selective agonists. Science 358:381-386
Arnsten, Amy F T; Girgis, Ragy R; Gray, David L et al. (2017) Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia. Biol Psychiatry 81:67-77
Pogorelov, Vladimir M; Rodriguiz, Ramona M; Cheng, Jianjun et al. (2017) 5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice. Neuropsychopharmacology 42:2163-2177
Lansu, Katherine; Karpiak, Joel; Liu, Jing et al. (2017) In silico design of novel probes for the atypical opioid receptor MRGPRX2. Nat Chem Biol 13:529-536
Urs, Nikhil M; Gee, Steven M; Pack, Thomas F et al. (2016) Distinct cortical and striatal actions of a ?-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties. Proc Natl Acad Sci U S A 113:E8178-E8186
Butler, Kyle V; Bohn, Kelsey; Hrycyna, Christine A et al. (2016) Non-Substrate Based, Small Molecule Inhibitors of the Human Isoprenylcysteine Carboxyl Methyltransferase. Medchemcomm 7:1016-1021

Showing the most recent 10 out of 128 publications